Trial Profile

A Multi-Center, North American, Randomized, Double-Blind, Parallel Group Study Comparing Three Doses of ACR16 Versus Placebo for the Symptomatic Treatment of Huntington Disease (HART)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 01 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pridopidine (Primary)
Indications Huntington's disease
Focus Therapeutic Use
Acronyms HART
Sponsors Teva Branded Pharmaceutical Products R&D; Teva Pharmaceutical Industries

10 Aug 2023 the protocol has been amended as above-1) phase has been changed from 2/3 to 2 . 2) primary endpoint has been changed.
22 Feb 2023 Results of pooled analysis assessing the pridopidine's effect on the QT interval and investigated its cardiac safety profile from NCT02006472, NCT00724048 and NCT00665223 trials, published in the Neurology and Therapy.
18 Jun 2015 Pooled safety analysis ( combination with antidepressants or antipsychotics), results presented at the 19th International Congress of Parkinson's Disease and Movement Disorders.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com